Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Neurocrine Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on the discovery, development, and commercialization of therapies for neurological, neuroendocrine, and psychiatric disorders. The company operates within the biotechnology and pharmaceutical industries, with a strategic emphasis on diseases involving dysregulated nervous and endocrine system signaling. Its business model integrates internal research and development with selective collaborations to advance both proprietary and partnered drug candidates.
The company’s primary revenue driver is INGREZZA, a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. Neurocrine’s unique positioning is built on deep expertise in neurobiology, strong clinical development capabilities, and a focused therapeutic scope rather than broad diversification. Founded in 1992, the company initially concentrated on neuroendocrine disorders and gradually evolved into a fully integrated commercial-stage biotechnology company following the successful launch of INGREZZA in 2017.
Business Operations
Neurocrine Biosciences operates primarily through a single integrated segment focused on the research, development, manufacturing oversight, and commercialization of pharmaceutical products. Revenue is generated mainly from U.S. product sales of INGREZZA, supplemented by collaboration revenue and milestone payments from strategic partners. The company does not operate manufacturing facilities at scale but relies on third-party manufacturers while retaining control over clinical development, regulatory strategy, and commercialization.
The company maintains active development programs across movement disorders, epilepsy, congenital adrenal hyperplasia, and schizophrenia. Key collaborations include long-standing partnerships with AbbVie Inc. related to elagolix-based products, under which Neurocrine receives royalties and milestone payments. Operations are primarily domestic, with international exposure occurring through licensing agreements and clinical development activities rather than direct commercial infrastructure.
Strategic Position & Investments
Neurocrine’s strategic direction centers on expanding its neuroscience-focused portfolio while maximizing the lifecycle value of INGREZZA through label expansions and new formulations. Growth initiatives emphasize advancing late-stage clinical programs, particularly in schizophrenia and rare neurological conditions, while maintaining disciplined capital allocation. The company consistently reinvests a significant portion of operating cash flow into internal R&D rather than pursuing large-scale diversification.
Notable investments include continued development of crinecerfont for congenital adrenal hyperplasia and multiple early- and mid-stage CNS pipeline assets. Neurocrine has historically favored targeted acquisitions and in-licensing over transformational mergers, prioritizing scientific fit and therapeutic adjacency. Emerging areas of focus include precision neuroendocrinology and novel mechanisms targeting brain signaling pathways.
Geographic Footprint
Neurocrine Biosciences is headquartered in San Diego, California, and its primary commercial operations are concentrated in the United States, which accounts for the majority of revenue. Research and development activities are also largely U.S.-based, supported by clinical trial sites across multiple countries.
International presence is primarily indirect, achieved through partnerships, licensing arrangements, and clinical trials conducted in Europe, Asia-Pacific, and other global regions. While the company does not maintain extensive overseas commercial operations, its products and pipeline have global relevance through regulatory submissions and collaborative agreements with multinational pharmaceutical partners.
Leadership & Governance
Neurocrine Biosciences was founded by Wylie Vale, whose academic research laid the scientific foundation for the company’s focus on neuroendocrinology. The current leadership team emphasizes long-term value creation through scientific rigor, disciplined execution, and a patient-centric development strategy. Governance is structured to support independence in research while maintaining strong oversight consistent with public-company standards.
Key executives include:
- Kyle W. Gano – President and Chief Executive Officer
- Kevin C. Gorman – Chief Operating Officer
- Matt Abernethy – Chief Financial Officer
- Eyal Attar – Chief Medical Officer
- Julie Cooke – Chief Commercial Officer